HYTN Innovations shareholders unanimously approved the spin-out of Peptide Development Labs (PDL) through a share exchange, where each HYTN share converts to one new HYTN share plus a fraction of a PDL share. The arrangement awaits final court and regulatory approvals and is expected to complete around November 17, 2026, with PDL shares to begin trading on the Canadian Securities Exchange (CSE) shortly after. This move allows HYTN to focus on psychoactive products while PDL advances peptide-based drug candidates. Shareholders also re-elected the board and auditors for HYTN.
HYTN Innovations' spin-out of Peptide Development Labs is the subject, with Pluang's Health-sector snapshot as of Nov 13, 2026 04:11 WIB showing 150 US health stocks priced, where 23 rose and 124 fell. Notable movers include BFLY at USD 6.64 with a -7.00% change, RXRX at USD 3.34 down 6.96%, and HRTX at USD 0.33 down 6.90%. The most notable figure is the breadth with 124 stocks falling today.
Super League Enterprise, a company specializing in audience intelligence and media activation for the gaming industry, announced it will release its financial results for the third quarter ending September 30, 2026, on November 16, 2026, after market...
Stantec Inc. reported a 9.4% increase in net revenue to $1.9 billion for Q3 2026, driven by organic and acquisition growth. Adjusted EBITDA rose 16.6% to $377.1 million with a record margin of 20.2%, while adjusted EPS grew 23.5% to $1.89. The compan...
Siemens reported earnings per share of $1.62 and revenue of $26.28 billion, both exceeding analyst expectations. The company saw record orders and double-digit revenue growth in its smart infrastructure and digital industries units, prompting it to r...
ASUS has introduced a broad ecosystem of AI-ready hardware and software designed for gamers, creators, developers, and enterprises. The ASUS Agent Computer initiative enables users to deploy AI locally, in the cloud, or via hybrid models, offering co...
The global cosmetic peptide synthesis market is projected to grow from $274 million in 2027 to $354.85 million by 2032, with a CAGR of 5.34%. Growth is fueled by rising demand for advanced anti-aging skincare ingredients, increased use of peptide-bas...
